RELAPSE/RECURRENCE
Clinical trials for RELAPSE/RECURRENCE explained in plain language.
Never miss a new study
Get alerted when new RELAPSE/RECURRENCE trials appear
Sign up with your email to follow new studies for RELAPSE/RECURRENCE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New trial aims to find best treatment for returning leukemia
Disease control Recruiting nowThis study tests whether a gentler, low intensity therapy works better than strong chemotherapy for people whose acute myeloid leukemia (AML) has come back or not responded to treatment. About 339 adults with AML in their first or second relapse will be randomly assigned to one o…
Matched conditions: RELAPSE/RECURRENCE
Phase: PHASE3 • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Disease control
Last updated May 09, 2026 05:18 UTC
-
New antibody drug combo offers hope for hard-to-treat lymphoma patients
Disease control Recruiting nowThis study tests whether adding the experimental drug lacutamab to standard chemotherapy (GemOx) helps people with a rare type of blood cancer called peripheral T-cell lymphoma that has returned or not improved after prior treatment. About 56 adults whose cancer cells have a spec…
Matched conditions: RELAPSE/RECURRENCE
Phase: PHASE2 • Sponsor: The Lymphoma Academic Research Organisation • Aim: Disease control
Last updated May 08, 2026 12:00 UTC
-
New hope for relapsed leukemia: Triple-Drug attack shows promise
Disease control Recruiting nowThis study tests a combination of three drugs (bugitinib, venetoclax, and cytarabine) in adults with a type of leukemia (AML) that has come back or not responded to standard treatment. The goal is to see if this combo can wipe out hidden cancer cells and keep patients in remissio…
Matched conditions: RELAPSE/RECURRENCE
Phase: PHASE2 • Sponsor: Shenzhen University General Hospital • Aim: Disease control
Last updated May 07, 2026 18:39 UTC